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Abstract
Background: Good adherence to treatment is crucial to control tuberculosis (TB). Efficiency and feasibility of directly
observed therapy (DOT) under routine program conditions have been questioned. As an alternative, Me ´decins sans
Frontie `res introduced self-administered therapy (SAT) in several TB programs. We aimed to measure adherence to TB
treatment among patients receiving TB chemotherapy with fixed dose combination (FDC) under SAT at the Homa Bay
district hospital (Kenya). A second objective was to compare the adherence agreement between different assessment tools.
Methods: We conducted a cross-sectional survey amongst a series of new TB patients receiving 6 months of standard TB
chemotherapy with FDC under SAT. Adherence was assessed at home with urine testing for Isoniazid (INH), pill count,
interviewer-administered questionnaire and visual analogue scale (VAS).
Results: In November 2008 and in June 2009, 212 of 279 eligible patients were assessed for adherence. Overall, 95.2%
[95%CI: 91.3–97.7] of the patients reported not having missed a tablet in the last 4 days. On the VAS, complete adherence
was estimated at 92.5% [95%CI: 88.0–95.6]. INH urine test was positive for 97.6% [95%CI: 94.6–99.2] of the patients. Pill
count could be assessed among only 70% of the interviewed patients. Among them, it was complete for 82.3% [95%CI:
75.1–88.1]. Among the 212 surveyed patients, 193 (91.0%) were successfully treated (cured or treatment completed). The
data suggest a fair agreement between the questionnaire and the INH urine test (k=0.43) and between the questionnaire
and the VAS (k=0.40). Agreement was poor between the other adherence tools.
Conclusion: These results suggest that SAT, together with the FDC, allows achieving appropriate adherence to
antituberculosis treatment in a high TB and HIV burden area. The use of a combination of a VAS and a questionnaire can be
an adequate approach to monitor adherence to TB treatment in routine program conditions.
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Introduction
Good adherence to tuberculosis (TB) treatment is crucial to cure
patients, to limit the development of drug resistance and to reduce
TB transmission in the community. For years, WHO has been
recommending the administration of drugs through directly
observed therapy (DOT) as part of the control strategy called
DOTS [1]. The efficiency and feasibility of DOT in routine health
care programs have been questioned for several reasons: i) DOT
requires well functioning and well staffed health services which
may not be available in some high burden and limited resource
countries [2,3]; ii) DOT is expensive, and time-consuming for
patients [4]; iii) the appropriateness of using DOT for TB
treatment in regions of high HIV prevalence where antiretroviral
treatments (ART) are self-administered may be questioned; iv)
DOT has not consistently been shown to be superior to other
approaches such as self-administered treatment (SAT) when
comparing cure or treatment completion rates [5]; v) DOT may
raise ethical issues regarding privacy and stigmatisation [6,7]. The
use of community DOT, if well monitored and supervised, can
solve some of these challenges [8]. Alternatively, Me ´decins sans
Frontie `res (MSF) has implemented SAT in several TB programs.
To ensure good adherence to TB treatment in these SAT based
programs, MSF promotes the use of fixed dose combinations
(FDC). FDCs, by considerably reducing the number of pills to
swallow, are likely to enhance adherence to treatment [9–11]. In
addition, FDCs may prevent the emergence of drug resistance and
have shown similar treatment outcomes as compared to separately
administered drugs [12]. The SAT approach should be associated
with patients-centred adherence strategies, including continuous
patient education and counselling, an adequate therapeutic
environment with a patient-health care provider relationship
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32140based on trust, respect, and involvement of the patient in his/her
treatment, as well as social support when necessary.
Regular adherence monitoring is essential to follow the quality
of SAT based TB programs. To date, few data have been reported
on adherence in such programs located in limited resource, high
HIV-TB burden settings [13].
Adherence monitoring is however a challenge due to the lack of
reliable tools [14]. The available tools include questionnaires,
visual analogue scales (VAS), urine tests for isoniazid (INH), pill
counts, and monitoring of pill collection regularity. All have
limitations and usually cover different treatment intake periods. It
is therefore recommended to combine tools in order to obtain a
reliable and valid estimate of patient adherence [15]. Although
some of these tools have been well evaluated for adherence to
antiretrovirals in HIV infected patients [16–22] and some of these
results could be extrapolated to TB patients, further evaluation in
TB is necessary.
The primary objective of this study was to measure adherence
to TB treatment among patients receiving 6 months of standard
TB chemotherapy with FDC under SAT in a limited resource,
high TB-HIV burden setting. A secondary objective was to
compare the agreement between different adherence assessment
tools.
Materials and Methods
Study setting
The study was conducted in Homa Bay district, Nyanza
province, in western Kenya. This area encompasses 360,000
inhabitants. The estimated TB incidence in Kenya was 305/
100,000 inhabitants in 2009 [23]. The HIV prevalence was 15.3%
in Nyanza province [24] and 24% in Homa Bay District [25]
where 74% of TB cases were HIV infected [26]. Since 2000, MSF
has been running a medical HIV/AIDS programme in Homa Bay
and has also been supporting the Ministry of Health TB clinic of
the district hospital. Newly diagnosed TB patients were receiving a
6 months of standard TB chemotherapy (fixed dose combination
of 2 months rifampicin (R), isoniazid (H), pirazinamide (Z) and
ethambutol (E), followed by 4 months of RH), using a self-
administrated approach. Patients collected the drugs weekly for
the first 2 months (intensive phase), and monthly for the last 4
months (continuation phase). Patients received the exact number
of pills necessary to cover the period between two visits at the
clinic. Treatments strategies were based on patient-centered
support and patients’ education. This individual-based approach
relied on a trusting relationship between care providers and
patients. In practice, health education was provided as a group
session by an ‘‘exemplary patient’’ to patients in the waiting area.
Individual adherence counselling was also given by a counselor at
the time of TB diagnosis and at each follow-up visit. Counselors
were available to provide specific in-depth patient support
according to the needs. In addition, food supplementation was
given to TB patients with a body mass index under 17.5 kg/m
2.
Provider initiated voluntary counselling and testing for HIV
infection was also systematically offered to all TB patients. None of
the component of these SAT strategy was changed for the purpose
of this study that aimed to evaluate adherence under routine
program conditions.
Study design and participants
We conducted a cross-sectional survey. Eligible patients were
new TB patients, aged at least 18 years, living in Homa Bay
District, with active pulmonary (both smear positive and negative)
or extra pulmonary TB and receiving a fixed dose combination of
2RHZE/4RH under SAT. Patients in prison were excluded as
well as patients with history of previous TB treatment (including
relapse, failure and return after default) because their treatment
regimen was not only based on FDC. We aimed to recruit all
patients who started treatment in the 6 months preceding the start
of the survey. These patients were identified through the TB
register of the TB clinic of the Homa Bay district hospital and
medical records. Patients who died or defaulted (interruption of
treatment for two consecutives months or more) before the time of
the survey could not be assessed for adherence. Also, patients
hospitalized at the time of the survey were not assessed for
adherence because their treatment regimen was not based only on
FDC under SAT at the hospital.
Consent for an unplanned home visit was asked to all eligible
patients when they presented at the TB clinic for a regular weekly
or monthly visit. The purpose of the unplanned home visit was not
explained. Patients who did not accept a home visit were
secondarily excluded. For patients accepting, information about
the survey was given at the patient’s home. Patients signing the
informed consent were included in the study and adherence was
assessed. A second home visit was conducted in case of absence of
the patient. If the patient was still absent at the second visit, he/she
was recorded as ‘‘absent’’.
Adherence assessment and data collection
Recent adherence (last 4 days) and adherence during the last
month were measured using simultaneously two subjective
(questionnaire and VAS), and two objective adherence monitoring
tools (urine test for INH and a pill count).
Self-reported recent adherence was measured by a standardised
interviewer-administered questionnaire. Patients were asked to
report the number of antituberculosis pills they took the day before
the survey as well as 2 days, 3 days and 4 days before the survey.
This number of pills was compared to number of pills prescribed
to the patient. The adherence to TB medication in the last 4 days
was classified as unsatisfactory (more than 25% of the pills missed
in the last 4 days, corresponding to more than one daily dose
missed), satisfactory (no more than 25% of the pills missed in the
last 4 days, corresponding to a maximum of one daily dose missed)
or complete (no missed pill in the last 4 days).
The patient’s adherence to TB medication in the last month was
assessed using a 10 points linear VAS (‘‘how much of your
prescribed TB medications have you taken in the last month?’’).
The adherence measured by the VAS was classified as
unsatisfactory (,80%, that is rating a value lower than 8 on the
VAS), satisfactory ($80% but less than 100%) or complete
(100%). The cut-off of 80% refers to the threshold used to define
compliance in the IUAT trial of various durations of INH
preventive therapy for TB [27]. The questionnaire and the VAS
were pre-tested before the survey.
The questionnaire also included questions on socio-demograph-
ic characteristics, reasons for non-adherence, and adherence
secondary endpoints (number of appointments missed, last time
when the patient missed a pill, the way patients followed the
medical prescription in the last month and a VAS on patient self-
confidence to successfully take the medication).
Pill count was calculated by comparing remaining pills (missed
or not yet taken), shown by the patient at home, and pills given to
the patient at the last visit at the TB clinic. As the exact total
number of pills delivered to the patient at the TB clinic was not
always properly recorded, the number of pills received by the
patient was calculated based on the prescription and the number
of days between the last visit to the clinic and the day of
assessment. Usually patients received treatment for 7 days during
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The calculated proportion of pills actually taken by the patient was
classified as unsatisfactory (,80%), satisfactory ($80% but less
than 100%) or complete (100%) [27].
BBL
TM Taxo
TM INH urine test strip was used to identify the
presence of INH in the patient urine. Results were classified as
positive or negative. The test has a good sensitivity to detect if INH
was ingested in the previous 24 to 36 hours. Some patients may
remain positive at 60 hours (28% positive) and 72 hours (4%) after
drug ingestion [28].
Adherence assessments was performed by eight teams that
included one medical and one non-medical person. The
surveyors were not part of the staff providing care to the patient.
All teams were trained in the study procedures. The question-
naire and the VAS were completed first and subsequently,
patients were asked to present their drugs container and the
remaining pills were counted. Urine was collected at the end for
INH testing.
Patients’ TB treatment outcomes were collected from the TB
register at the TB clinic. The outcomes were classified following
the standard WHO definitions [29].
Sample size and statistical analysis
To measure the proportion of patients with complete adherence
with a 10% precision on the estimate, we needed to recruit 81
patients considering an expected 70% complete adherence rate
during the intensive phase and 97 patients considering an expected
50% adherence rate during the continuation phase (a=0.05).
Expecting about one third of the patients in the intensive phase of
treatment, we needed to include a series of 243 patients.
For each adherence measurement tool, the proportions of
patients with complete, satisfactory and unsatisfactory adherence
were calculated. The proportions of patients with complete
adherence were presented with exact 95% confidence intervals
(95%CI).
Agreement between adherence measurements was assessed
using the kappa coefficient. The maximum attainable kappa, that
is the maximum value of the kappa coefficient attainable for this
set of data and the prevalence index were also calculated [30].
Because there is no gold standard tool to measure the adherence to
TB treatment, a latent class analysis (LCA) was used to estimate
the true prevalence of satisfactory adherence and to assess the
posterior probability of being adherent [31,32]. LCA assumes that
patients can be classified in two groups: adherent and non-
adherent and allows computing the probability of being adherent
for each combination of adherence measurement tools.
Data were analysed using StataH 9 software (College Station,
Texas, USA).
Ethics
The study was approved by the scientific and ethical review
committees of the Kenyan Medical Research Institute (KEMRI) in
Nairobi and the Committee de Protection des Personnes de St
Germain en Layes, France.
Written informed consent was obtained from each patient
before participation.
Patients with poor adherence were offered additional adherence
support and counselling.
Results
Participants
In order to obtain the estimated sample size, the survey was
performed in two stages: November 2008 and June 2009. All
eligible patients who started TB treatment between May and
October 2008 (n=132) were investigated in November 2008 and
patients who started TB treatment between December 2008 and
June 2009 (n=147) were investigated in June 2009. There was no
statistical evidence for a difference in the characteristics of the
two series of patients (data not shown). Of the 279 eligible
patients, 67 were not interviewed: 25 (9.0%) had defaulted prior
to asking consent for a home visit, 14 could not be located (5.0%),
13 (4.7%) did not consent for a home visit, 11 (3.9%) were dead
and 4 (1.4%) were hospitalised by the time of the survey
(Figure 1). Socio-demographic and medical characteristics of the
212 patients included in the adherence assessment are presented
in Table 1. One third (73/212) of the patients where helped by
another person for treatment intake. About half of these people
(56.5%) were present when the patient was answering the
questionnaire.
Adherence
Adherence was assessed in a median delay of 2 days after the
last visit at the TB clinic (min-max: 0–7) for patients in the
intensive phase of treatment, and of 8 days (min-max: 0–41) for
patients in the continuation phase of treatment.
The estimated level of adherence was high using all the
adherence measurement tools (Tables 2 and 3). Overall, 95.2%
[95%CI: 91.3 to 97.7] of the patients reported not having missed a
pill in the last 4 days. On the VAS, complete adherence was
estimated at 92.5% [95%CI: 88.0 to 95.6]. Urine INH test was
positive for 97.6% [95%CI: 94.6 to 99.2] of the patients. Pill count
Figure 1. Survey Profile.
doi:10.1371/journal.pone.0032140.g001
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The proportion of pills taken by the patient was classified as
complete for 82.3% [95%CI: 75.1 to 88.1]. Except for the VAS,
main adherence results tended to be better during the intensive
phase than during the continuation phase. The differences were
not statistically significant although there was a trend for the pill
count (Table 2). There was no significant difference in adherence
neither between HIV infected and non infected patients nor
between patients on ART and patients not on ART (data not
shown).
For 16 patients (7.5%), adherence was classified as unsatisfac-
tory by at least one of the 4 tools. Taking in consideration the 4
tools and excluding patients with missing data for any one of the 4
tools, 91.1% [133/146; 95%CI 85.3–95.2] of patients interviewed
had a satisfactory adherence on all the 4 adherence measurements
tools (INH test positive, VAS$80%, questionnaire $75%, pill
count $80%). The LCA model estimated the prevalence of true
satisfactory adherence at 99% [95%CI 97–100%] . If the 25
patients who defaulted before being asked consent for a home visit
were included in the estimation of the adherence level and
considering that all of them would have had a non-satisfactory
adherence, the overall adherence would have been 77.8% (133/
171) [95%CI 70.8–83.8].
Reasons for non-adherence were reported by 17 patients who
had missed at least one pill through the questionnaire and/or the
VAS. The main reasons were: running out of pills (22%), being
away from home (19%) or forgetting to take the medication (17%).
Among the 212 surveyed patients, 193 (91.0%) were successfully
treated (cured or treatment completed) (Table 4). Among the 279
eligible patients, the success rate was 78.9%. The proportion of
unfavourable outcomes (death, failure, or default excluding
patients transferred out) tended to be lower in the group of
patients with satisfactory adherence (13/192, 6.8%) than in the
group of patients with unsatisfactory adherence by at least one of
the 4 tools (2/16, 12.5%; p=0.32) but the difference was not
statistically significant.
Tools agreement
The data suggest a fair agreement between the questionnaire
and the INH urine test (k=0.43) and between the questionnaire
and the VAS (k=0.40) (Table 5). Agreement was poor between
the other adherence tools (k,0.40). Due to the high number of
missing values, the pill count was not included in the LCA model.
According to the LCA model, having an adherence classified as
satisfactory by at least two of the three tests (INH and/or VAS
and/or questionnaire) gave a posterior probability of being
satisfactory adherent equal to 1 (Table 6). Posterior probability
of being satisfactory adherent with an adherence classified as
satisfactory by only one of the three tests was inferior or equal to
0.5. Predicted frequencies by the model show the good fit of the
data.
Discussion
The results of this study suggest a good adherence to the self-
administered TB treatment with FDCs for new TB cases in Homa
Bay district, western part of Kenya. Both recent adherence
(measured through questionnaire and INH test) and last month
adherence (measured through VAS) to TB treatment were good.
There was no evidence for a difference in adherence during
intensive and continuation phase of the TB treatment. Similar
good adherence has been previously reported using SAT in a slum
in Nairobi [13] and experiences from various countries have
shown that interventions such as enabling patients to take
responsibility for their health or increasing flexibility in terms of
patient choice of treatment strategy, could improve adherence to
TB treatment [33,34]. The main reason of non adherence
reported by the patients was running out of pills, as reported in
other African settings [35]. The reason for running out of pills was
likely to be explained by missed appointment or loss of pills. The
second reason was being away from home, mainly due to the
economic activities in the area. In contrary to previous studies,
feeling better or drugs side effects were not frequently reported as
reasons for non adherence [35–37].
This cross-sectional study has several limitations: i) This design
allows a rapid assessment easily replicated in other programmes or
other time periods but can only measure adherence at one point of
time and does not allow assessing the variation of adherence over
the full length of treatment compared to the use of a prospective
cohort study [38]. ii) Twenty four percent of the eligible survey
population were not assessed for adherence. The exclusion of
patients who defaulted before the survey was related to the use of a
cross-sectional design and resulted in an overestimation of the
adherence. Nevertheless, even when adherence to treatment was
estimated including the defaulters and considering them as non-
adherent, the adherence level remained fairly good, close to 80%.
Similarly, some patients were not interviewed because either they
died before the survey; were hospitalised at the time of the survey;
could not be located or refused to consent for an home visit. iii)
Adherence was assessed among patients who had come recently to
collect their pills at the TB clinic. This may have overestimated the
Table 1. Baseline characteristics of the participants.
n (%) Total
(n=212)
Socio-demographic characteristics
Mean age (years) 6 standard deviation 35.0611.9
Female 98 (46.2)
Education: Never went to school 10 (4.7)
Incomplete primary 76 (35.9)
Complete primary 52 (24.5)
Incomplete secondary 24 (11.3)
Complete secondary 32 (15.1)
Higher level 18 (8.5)
Distance home-clinic (km): 0-,5 km 114 (55.9)
5-,10 km 48 (23.5)
10 km or more 42 (20.6)
Residence area: Rural 102 (48.6)
Urban 108 (51.4)
Medical characteristics
Pulmonary tuberculosis 167 (78.8)
Weeks between the start of the treatment and the survey:
Median (minimum – maximum) 12.7 (0.9–
24)
1 to 7 (intensive phase) 64 (30.2)
8 to 24 (continuation phase) 148 (69.8)
HIV Positive (n=202)* 153 (75.7)
HIV positive under ART (n=103)** 75 (72.8)
*10 missing data.
**ART data missing for 50 HIV positive.
doi:10.1371/journal.pone.0032140.t001
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days surrounding clinical appointment [14]. iv) Another limitation
was the high number of missing values for the pill count. This is
mostly explained by the fact that, for several patients, it was
difficult to know exactly how many pills they have received at the
last appointment to the TB clinic, and that some surveyors, at the
beginning of the survey, included erroneously the pyridoxine in
the TB pill count. v) Finally, self-reported adherence measures are
prone to social desirability bias as patients might tend to provide
answers that would fit the surveyors expectations (that is, good
adherence to treatment). We tried to limit this bias by working
with surveyors who were not part of the staff providing care to the
patient.
Since there is no gold standard to assess adherence to TB
treatment, it is suggested to use a combination of adherence
monitoring tools [15]. The Medication Event Monitoring System
Table 2. Adherence (main endpoints) of the participants according to the phase of treatment (n=212).
Intensive Continuation p* All
n( % ) n( % ) n( % )
Adherence according to questionnaire** 0.40
Complete (no missed pill last 4 days) 61 (96.8) 137 (94.5) 198 (95.2)
Satisfactory (max 25% missed last 4 days) 2 (3.2) 4 (2.8) 6 (2.9)
Unsatisfactory (.25% missed last 4 days) 0 (0.0) 4 (2.8) 4 (1.9)
VAS: ‘‘how much of your prescribed TB medications have you taken in the last month’’ 0.84
Complete (100%) 59 (92.2) 137 (92.6) 196 (92.5)
Satisfactory ($80%) 5 (7.8) 10 (6.8) 15 (7.0)
Unsatisfactory (,80%) 0 (0.0) 1 (0.6) 1 (0.5)
INH test Positive 64 (100) 143 (96.6) 0.33 207 (97.6)
Negative 0 (0.0) 5 (3.4) 5 (2.4)
Pill count*** 0.08
Complete (100%) 49 (90.7) 72 (77.4) 121 (82.3)
Satisfactory ($80%) 2 (3.7) 14 (15.1) 16 (10.9)
Unsatisfactory (,80%) 3 (5.7) 7 (7.5) 10 (6.8)
*Fisher exact.
**4 missing data.
***65 missing data or inconsistencies.
doi:10.1371/journal.pone.0032140.t002
Table 3. Adherence (secondary endpoints) of the participants according to the phase of treatment (n=212).
Intensive Continuation p* All
n( % ) n( % ) n( % )
$1 appointment(s) missed for drug collection 0 (0.0) 5 (3.4) 0.33 5 (2.4)
Last time reported to have missed a pill** 0.84
Never missed a pill 55 (93.2) 128 (90.1) 183 (91.0)
Last 4 days 2 (3.4) 5 (3.5) 7 (3.5)
More than 4 days ago 2 (3.4) 9 (6.3) 11 (5.5)
Regarding your TB treatment, in the last month, how did you follow the medical prescription: 0.60
Strictly 59 (95.1) 143 (96.6) 202 (96.2)
Approximately with few deviations 3 (4.8) 4 (2.7) 7 (3.3)
With many deviations 0 (0.0) 1 (0.7) 1 (0.5)
Rarely/Did not take any pill 0 (0.0) 0 (0.0) 0 (0.0)
Never stop taking pill for more than 2 days 60 (95.2) 136 (93.8) 1.0 196 (94.2)
VAS: ‘‘how confident do you feel you can successfully take your medication’’ 0.001
100% 56 (87.5) 143 (96.6) 199 (93.9)
$80% 8 (12.5) 2 (1.4) 10 (4.7)
,80% 0 (0.0) 3 (2.0) 3 (1.4)
*Fisher exact.
**11 missing data.
doi:10.1371/journal.pone.0032140.t003
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adherence [14]. It is an electronic device included in a drug
container, which records the date and hour of each opening.
However, this device is very technical, it is expensive and does not
ensure that the patient actually ingested the pill. For these reasons
as well as for operational reasons, we decided not to use it in this
survey. We used a combination of objective (INH urine test, pill
count) and subjective tools (VAS and questionnaire). Studies using
pill count, VAS and questionnaires in monitoring adherence to
HIV treatment have reported good agreement between question-
naires and VAS [17,19], pill count and VAS [16,19] or
questionnaire [18,19], and between different measures of self-
reported adherence [20,21]. We expected similar results but the
observed agreement between the adherence measurement tools
used in this survey was low (kappa#0.43) as well as most of the
estimated maximum attainable kappa. The kappa coefficients
should be interpreted with caution as confidence intervals were
wide, the sample of patients selected for adherence assessment was
likely to be more homogeneously adherent, and the low prevalence
of non-adherence [30] might have influenced the magnitude of the
coefficients. Nevertheless, this low agreement could also be
explained by the fact that each adherence measurement tool was
measuring different components of adherence, over different time
periods, which gives another reason to combine different tools to
monitor adherence.
In the absence of gold standard to measure adherence to TB
treatment, we decided to use a LCA model. In this model, the
combination of two out of three adherence measurement tools
(INH test, questionnaire, VAS) predicted very well the adherence
to TB treatment. Due to the number of missing values, it was not
possible to include the pill count in the model.
INH urine test is the most objective tool for monitoring of
adherence to TB treatment. However, it only reflects recent dose
intake and, therefore, if performed in the health facility, INH urine
test might overestimate the adherence level of patients as they may
tend to ingest pills just before their visit. Also, the relatively high
price, the supply constraints and the storage condition (cold chain)
of this manufactured test make it difficult to use in routine
conditions. Although these limitations may be partly overcome by
the possibility of making local non commercial tests for a much
cheaper cost [39,40], a urine test may appear intrusive for the
patient and might not be suitable to monitor adherence routinely
under program conditions. In addition, pill count has been shown
to be a reliable tool for monitoring of adherence to HIV treatment
[18]. However, the accuracy of a clinic-based planned pill count
may be easily distorted by the patient and is limited by patients
failing to bring all their pills to the clinic. Also, as the INH test, pill
count appears contradictory to patient’s empowerment. On the
contrary, questionnaires and VAS have been described to be easy
to use, non intrusive and cheap tools to measure both recent and
last month adherence [19]. Pictographic and color VAS have been
shown to be valid and useful tools in assessing medication
adherence in lower-literacy populations [41]. Thus, these tools
seem to be well adapted to programmatic conditions after training
on their use.
In conclusion, this survey conducted in routine program
conditions has shown that self-administered therapy together with
the FDC and patient centred adherence strategies allows achieving
appropriate adherence to antituberculosis treatment in a high TB
and HIV burden area. This strategy is well adapted to limited
Table 4. TB treatment outcome.
n( % )
Patients
surveyed All eligible patients
(n=212) (surveyed or not; n=279)
Success* 193 (91.0) 214 (78.9)
Death 6 (2.8) 19 (7.0)
Failure 4 (1.9) 4 (1.5)
Default 5 (2.4) 30 (11.1)
Transferred out 4 (1.9) 4 (1.5)
Missing data / 8
*Cured or treatment completed.
doi:10.1371/journal.pone.0032140.t004
Table 5. Agreement between adherence measurement tools.
Questionnaire
,75%
Questionnaire
$75% Total
VAS ,80% 10 1
VAS $80% 3 204 207
Total 4 204 208
k: 0.40 Maximum attainable
k: 0.40
Prevalence index: 0.98
Questionnaire
,75%
Questionnaire
$75%
INH test 2 23 5
INH test + 2 201 203
Total 4 204 208
k: 0.43 Maximum attainable k:
0.87
Prevalence index: 0.96
Questionnaire
,75%
Questionnaire
$75%
Pill count ,80% 19 1 0
Pill count $80% 1 135 136
Total 2 144 146
k: 0.15 Maximum attainable k:
0.32
Prevalence index: 0.92
VAS ,80% VAS $80%
INH test 2 14 5
INH test + 0 207 207
Total 1 211 212
k: 0.33 Maximum attainable
k: 0.33
Prevalence index:
0.97
VAS ,80% VAS $80%
Pill count ,80% 19 1 0
Pill count $80% 0 137 137
Total 1 146 147
k: 0.17 Maximum attainable k:
0.17
Prevalence index: 0.93
INH test 2 INH test +
Pill count ,80% 19 1 0
Pill count $80% 2 135 137
Total 3 144 147
k: 0.13 Maximum attainable k:
0.44
Prevalence index: 0.91
doi:10.1371/journal.pone.0032140.t005
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extrapolated in settings where single antituberculosis drugs are
administered separately. Although the use of a combination of two
simple tools, such as the VAS and a questionnaire, might be an
adequate approach to monitor adherence to TB treatment in
routine program conditions, further validation is required. Also, in
the future, other tools might play a role in the support and
monitoring of adherence to TB treatment, in particular commu-
nication devices such as mobile phones, which are more and more
available in high burden and limited resource countries [42,43].
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